Diclofenac Potassium vs Sodium — A Distributor and Pharmacist Guide

The same drug in two salt forms

Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) widely used in Nigeria for pain and inflammation across dental, musculoskeletal, gynaecological and post-surgical indications. It is marketed in two principal salt forms:

• Diclofenac potassium — the potassium salt, marketed in Nigeria as Relagesic (Dizpharm), Cataflam (Novartis originator), and other generics.
• Diclofenac sodium — the sodium salt, marketed in Nigeria as Voltaren (Novartis originator), and numerous generics. Often supplied as enteric-coated tablets.

The active pharmacological species in both — once absorbed and circulating — is identical. The difference is the rate at which the drug becomes available in the bloodstream after administration.

Why the potassium salt is faster

The potassium salt of diclofenac is more water-soluble than the sodium salt. When swallowed, the potassium-salt tablet dissolves more rapidly in the stomach, the drug is absorbed faster across the upper-GI mucosa, and effective plasma concentrations are reached sooner. Typical onset of analgesia is approximately 15-30 minutes for diclofenac potassium versus 30-60 minutes for an enteric-coated diclofenac sodium preparation.

The total drug exposure (the area under the plasma concentration-time curve) is similar between the two salts at equivalent doses. The salts deliver the same drug; the potassium salt just delivers it sooner.

When the potassium salt is preferred

Clinical scenarios where rapid onset is the priority:

• Dental pain — acute toothache and post-extraction pain. Patients want relief in minutes, not hours.
• Period pain (dysmenorrhoea) — onset of menstrual cramping is sudden; faster relief is meaningful to patient experience.
• Post-surgical and post-injury pain — early-window analgesia where rapid onset matters.
• Acute migraine and tension headache — headache management is largely an onset story.
• Acute gout flare — rapid suppression of inflammation in joint flare-ups.
• Renal colic and acute musculoskeletal pain — wherever the clinical goal is fast relief.

When the sodium salt is preferred

Clinical scenarios where sustained anti-inflammatory effect is the priority and onset speed is less important:

• Chronic arthritis (osteoarthritis, rheumatoid arthritis) — daily maintenance dosing.
• Chronic musculoskeletal pain — back pain, chronic joint disease.
• Where gastric protection is a higher priority — enteric coating on sodium salt provides some additional gastric protection (though this is not absolute and PPI co-therapy is often still appropriate).
• Where the patient is established on a specific brand — continuity of care.

Cautions, contraindications and side effects

Cautions and contraindications are essentially identical between the two salts — they share the same NSAID class effects:

• GI risk — both salts can cause dyspepsia, gastric ulceration and GI bleeding. Avoid in patients with active peptic ulcer disease; co-prescribe PPI in higher-risk patients.
• Cardiovascular risk — NSAIDs (including diclofenac) carry cardiovascular risk; caution in patients with established cardiovascular disease.
• Renal function — avoid or reduce dose in renal impairment; both salts affect renal perfusion.
• Pregnancy — avoid in the third trimester; specialist consultation in earlier pregnancy.
• Allergy and asthma — contraindicated in patients with NSAID hypersensitivity or aspirin-sensitive asthma.
• Interaction caution — interactions with anticoagulants, certain antihypertensives, methotrexate, lithium and other drugs.

None of these caution profiles is significantly different between the potassium and sodium salts at equivalent doses.

Distributor positioning at retail

For a distributor or pharmacy choosing between stocking diclofenac potassium and diclofenac sodium, the practical answer is usually both, positioned correctly:

• Diclofenac potassium (Relagesic, Cataflam-class) — promote as the fast-onset analgesic for dental, menstrual, post-injury and acute musculoskeletal pain. Mid-to-higher unit margin; rapid reorder cycle in pharmacies near dental clinics, maternity hospitals and gym/physio practices.
• Diclofenac sodium (Voltaren-class) — promote as the maintenance NSAID for chronic arthritis and sustained musculoskeletal pain. Steady reorder cycle in pharmacies serving older buyer demographics and clinics treating chronic disease.

For most general pharmacy and PPMV buyer mixes, diclofenac potassium has a faster turnover (because acute-pain customers come back more often), while diclofenac sodium serves a smaller but more loyal chronic-pain base.

Relagesic 50 from Dizpharm

Relagesic 50 is Dizpharm's NAFDAC-registered diclofenac potassium 50mg tablet — manufactured at our GMP-certified Ibusa facility to BP standard, and the fast-onset alternative in the same active class as branded products like Cataflam. See the wholesale page for distributor carton pricing and indications, or contact us on WhatsApp for a quote.

Frequently asked questions